Tuesday, February 19, 2008 |
| 8:00 | Registration and Continental Breakfast |
| 8:30 |
Welcomes
NIEHS - Beth Anderson
Steering Committee- Frederic Pfaender |
| 8:45 |
Plenary Address- Context of bioavailability from the environment
to patients. David Nakles, ENSR |
| Session 1- Day 1, AM |
| Uncertainties in Environmental Control of Bioavailability |
| Objectives: Defining what we do not understand about how the sequestration of chemicals is controlled by environmental properties and processes, and how this relates to the exposure concentration. |
| 9:30 | Factors Affecting the Bioavailability of Contaminants in Soil and Sediment- Joseph Pignatello, Connecticut Agricultural Experiment Station (confirmed) |
| 10:00 |
Environmental Control of Metal Bioavailability- Dominic Di Toro, Delaware (confirmed) |
| 10:30 |
Coffee Break |
| 10:45 |
Uncertainies of Remediation Processes on Bioavailability -
David Ellis, DuPont (confirmed) |
| 11:15 |
Discussion:
- What are relevant environmental measures for exposure and human health?
- What environmental and biological information do we need to predict bioavailability?
- How do we assess in natural settings the successful remediation of organic or inorganic contaminants that are sequestered or otherwise have low bioavailability?
|
| 12:30 |
Lunch |
| Session 2 - Day 1, PM |
| Uncertainties in Host Factor Control of Bioavailability |
| Objectives: Examining host factor influences over bioavailability. |
| 1:30 |
Disease Types and Their Impact on Bioavailability - Steven Roberts,
Florida (confirmed) |
| Impact of Nutritional Status |
| 2:00 |
Impact of Underlying Nutritional Status - Rosalind
Schoof, Integral Inc. (confirmed)
|
| 2:30 |
Impact of GI Track Status During Exposure - Mark Maddaloni,
EPA (confirmed) |
| 3:00 |
The Impact of Age on Bioavailability- Gary Diamond, SRC (confirmed) |
| 3:30 |
Coffee Break |
| 4:00 |
Discussion
- How important are gender and genetic factors in estimating bioavailability?
- How does food in the digestive tract impact bioavailability?
- What is the impact of nutritional deficiencies on site specific bioavailability?
- Which underlying disease states impact bioavailability?
|
| 5:30 |
Poster Session |
Wednesday, February 20, 2008 |
| 8:00 |
Continental Breakfast |
| Session 3 - Day 2, AM |
| Methods for Measuring Bioavailability |
| Objectives: Examining the methods currently employed to assess bioavailable contamination and those that show promise for the future. This session will consider methods used in human and ecological toxicology and those with potential for rapid assessment of regulated media. |
| 8:30 |
Emerging Technologies for Assessment of Environmental Bioavailability and Exposure- Damien Shea, NCSU (confirmed) |
| 9:00 |
Uncertainty of in vitro GI models developed of organic / inorganic contaminant bioavailability to humans- Nicholas Basta, Ohio State (confirmed) |
| 9:30 |
Emerging Nanotechnologies for Intracellular Chemical Imaging,
Medical Imaging and Therapy- Martin Philbert, Michigan (confirmed) |
| 10:00 |
Coffee Break |
| 10:30 |
Emerging Contaminants - Aleksandr Stefaniak, NIOSH (confirmed) |
| 11:00 |
Discussion
Potential Discussion Questions:
- What can be done to better validate models?
- How do we extrapolate models between different chemicals?
- What are valid methods other than bioassay?
- How does cost and time relate to choice of methods?
|
| 12:30 |
Lunch |
| Session 4- Day 2, PM |
| The Weight of Evidence for Adjusting Exposure Based on Bioavailability |
| Objectives: Establishing the burden of proof required to use bioavailabilty to adjust the exposure assessment. |
| 1:30 |
EPA Oral Bioavailability Guidance- Michael Beringer, EPA (confirmed) |
| 2:00 |
Point - Counterpoint Discussion- The FMC Site- Mark Maddaloni,
EPA and Rosalind Schoof, Integral Inc. (confirmed) |
| 2:30 |
Investigations of the Use of Bioavailability Data When Setting
Occupational Exposure Limits for Active Pharmaceutical Ingredients - Edward
Sargent, Merck (confirmed) |
| 3:00 |
Persuasive power of bioavailability information in stimulating
intervention at the community level - Edward Emmett, Penn (confirmed) |
| 3:30 |
Coffee Break |
| 3:45 |
Discussion
- What can we do to extrapolate from environmental assessments to human models?
- What adjustments to risk models are necessary to include BV? Which are defendable?
- How do we convince the public that risk assessment adjustment is valid?
|
| 5:00 |
Poster session- If needed |
Thursday, February 21, 2008 |
| 8:00 |
Continental Breakfast |
| Session 5- Day 3, AM |
| Applying Bioavailability Data to Achieve Site Closure |
| Objectives: Examining the incorporation of bioavailability data into regulatory frameworks for assessing risk and establishing remedial action objectives. |
| 8:30 |
Developing effective risk communication - Wandi Bruine de Bruin, Carnegie-Mellon
(confirmed) |
| Metals in Soil Case - Leadville, CO |
| 9:00 |
Technical Background- Yvette Lowney, E/x/ponent (confirmed) |
| 9:30 |
Regulatory Perspective- Susan Griffin, EPA (confirmed) |
| 10:00 |
Coffee Break |
| Organics in Sediment Case Study- State of New York |
| 10:15 |
Technical Background- E. Neuhauser, National Grid (confirmed) |
| 10:45 |
Regulatory Perspective- T. Sinnott, New York State Department of Environmental Conservation (confirmed) |
| 11:15 |
Discussion - H. Stroo, HGL
- What is the necessary burden of proof?
- Are more large, multi-disciplinary studies needed and if so, what matrices and/or contaminants should be the focus of such studies?
- What can we learn from efforts to date about how to design, manage, and interpret studies intended to modify clean up criteria to reflect bioavailability?
|
| 12:30 |
Lunch |
| Session 6- Day 3, PM |
| Summary and Discussion |
| Objectives: Generate summaries and research agendas from the previous discussions in relation to the questions. |
| 1:30 |
Panel Discussion of Big Picture Questions from Agency Perspective
Panel composed of :
EPA- Dr.Randy Wentsel
CDC/ATSDR- Dr. Moiz Mumtaz
NIEHS- Msw Beth Anderson
NIOSH- Dr. Mark Hoover
SERDP- Dr. Andrea Leeson |
| 2:30 |
Open discussion of Big Picture Questions |
| 3:30 |
Closing remarks
Dr. Frederic Pfaender
Ms. Beth Anderson |
| 3:45 |
Adjourn |
